Agentix Corp.

Agentix Corp. is a clinical-stage biopharmaceutical company that focuses on developing treatments for metabolic disorders, including type 2 diabetes, obesity, and fatty liver disease. The company's therapeutic pipeline centers on peripherally-restricted cannabinoid type 1 receptor antagonists and inverse agonists designed not to cross the blood-brain barrier. Its primary product candidates include AGTX-2004, a CB1 receptor antagonist advancing toward human clinical trials, and AGTX-2003, an inverse agonist undergoing preclinical evaluation. Because its drug candidates remain in development without commercial sales, the firm has no commercial customers, though it aims to partner with larger pharmaceutical corporations.

The company manages development activities through an operational subsidiary, Agentix Australia Pty Ltd, located in Australia. It maintains no full-time or part-time employees, with corporate affairs overseen by a director. Agentix does not rent or own physical real estate or facilities, maintaining its corporate headquarters at a virtual office address in Dana Point, California.

Summary of the business section of Agentix's latest annual report, written by StockData.